iMing Stock (OTC:IMNG), Trade Ideas

iMing Corp is a technology solution provider of set-top boxes (STB). It provides web-based television and videos for the Chinese Market. The company supplies high-definition television through the Web (Web TV) in China, turning the internet into the content delivery source which is displaying on their television or monitor. The products offered by the company includes iMing Web TV HD Box, iMing Smart TV and smartphone accessories.

iMing Corp

News

Management

Pharmacy Guild Says Pharmacy Professionals At CVS Omnicare In Las Vegas Vote Overwhelmingly To Form Union With The Pharmacy Guild

Shares of major U.S. energy companies experienced widespread declines in the first hour of trading on Friday, subsequent to the recently released subdued earnings reports from oil giants Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) and Chevron Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>).
The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>), a gauge for energy sector performance, experienced a 1.7% drop, setting it up for its worst session since <a href="https://www.benzinga.com/money/best-energy-stocks">the end of January.</a>
<h1 class="wp-block-heading">Chart: Energy Stocks Witness Their Sharpest Decline Since Late January As Major Oil Giants Disappoint</h1>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="495" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26112544/image-239-1024x495.png" alt="" class="wp-image-311157" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26112544/image-239-1024x495.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26112544/image-239-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26112544/image-239-768x372.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26112544/image-239-1536x743.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/26112544/image-239.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
What Happened: Exxon Mobil reported a disappointing start to the year with its first-quarter earnings missing the mark. 
The oil giant posted an earnings per share (EPS) of $2.06, falling short of the forecasted $2.189. 
Although revenue exceeded expectations at $83 billion against an anticipated $79.7 billion, its net production dipped slightly from 3.83 million oil-equivalent barrels per day the same period last year to 3.78 million oil-equivalent barrels per day.
The adjusted net profit also declined to $8.22 billion from $11.62 billion a year earlier, affected by lower refining margins and natural gas prices.
Read Also:<a href="https://www.benzinga.com/news/earnings/24/04/38459221/exxon-mobils-stock-slides-following-q1-earnings-heres-why"> Exxon Mobil&#8217;s Stock Slides Following Q1 Earnings &#8211; Here&#8217;s Why</a>
Chevron managed to align more closely with analyst expectations, delivering an EPS of $2.93 compared to the projected $2.99. 
Revenue saw a slight beat at $48.7 billion versus $48.4 billion. Chevron&#8217;s upstream business exceeded forecasts, posting earnings of $5.501 billion versus the $5.12 billion expected, although the first quarter print lower than the previous year&#8217;s $6.574 billion.
Chevron also provided updates on its ongoing merger process with Hess Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>), indicating progress towards compliance with regulatory requirements.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/04/38458299/chevrons-strategic-advances-in-oil-production-overshadowed-by-q1-revenue-miss">Chevron&#8217;s Strategic Advances In Oil Production Overshadowed By Q1 Revenue Miss</a>
Furthermore, another oil player, Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>), which ranks as the seventh-largest constituent in the XLE ETF, also reported earnings and revenue <a href="https://www.benzinga.com/news/earnings/24/04/38461749/why-petroleum-refineries-major-phillips-66-shares-are-falling-today">that fell below expectations.</a>
Why It Matters: Energy has stood out as the top-performing sector in the S&amp;P 500 this year, with the XLE gauge climbing 14%. However, this leading edge is now diminishing as major oil companies such as Exxon Mobil and Chevron pull back.
Together, Exxon and Chevron represent approximately 40% of the holdings in the prominent energy-related ETF, underscoring their significant influence on the sector. 
Should their stocks not rebound, the implications could extend beyond these industry giants, potentially affecting the performance of smaller entities within the sector.
Market reactions: As of 11:15 a.m. ET, Exxon Mobil Corp.&#8217;s shares had dropped nearly 4%, marking their potential worst day since mid-March 2023. 
Chevron Corp.&#8217;s shares declined by a modest 0.8%, threatening to end a seven-day streak of gains. 
Additionally, Phillips 66 experienced a sharp decline, falling 4% and setting up what could be its worst trading day since October 2023.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Energy company</td>
<td>% Weight in XLE</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>Exxon Mobil Corporation</td>
<td>23.24</td>
<td>-4.01%</td>
</tr>
<tr>
<td>Chevron Corporation</td>
<td>16.84</td>
<td>-0.80</td>
</tr>
<tr>
<td>ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>)</td>
<td>9.00</td>
<td>-0.46</td>
</tr>
<tr>
<td>EOG Resources, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>)</td>
<td>4.64</td>
<td>-0.34</td>
</tr>
<tr>
<td>Marathon Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>)</td>
<td>4.31</td>
<td>-1.34</td>
</tr>
<tr>
<td>Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) </td>
<td>4.15</td>
<td>-0.74</td>
</tr>
<tr>
<td>Phillips 66 </td>
<td>3.97</td>
<td>-4.03</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">updated at 11:15 a.m. EDT</figcaption></figure>
Read Now: <a href="https://www.benzinga.com/news/large-cap/24/04/38441405/gold-glitters-on-stagflation-tailwinds-newmont-soars-13-in-biggest-gain-post-covid-leads-mining-se">Gold Glitters On Stagflation Tailwinds: Newmont Soars 13% In Biggest Post-Covid Gain, Leads Mining Sector Surge</a>
This image was created using artificial intelligence MidJourney

Earnings Misses

Large Cap

Mid Cap

Sector ETFs

Commodities

Markets

ETFs

US Energy Stocks Fall Following Oil Giants' Subdued Earnings Reports

Goldman Sachs analyst Brooke Roach maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Neutral and lowers the price target from $14 to $12.5.

Price Target

Analyst Ratings

Goldman Sachs Maintains Neutral on VF, Lowers Price Target to $12.5

Robert Herjavec is not just a shark in the boardroom but also in real estate as he lists his New York City penthouse for $38.5 million.
The renowned "Shark Tank" investor and entrepreneur's 6,240-square-foot apartment spans an entire floor of One57, a 75-story skyscraper on Manhattan's Billionaire's Row, according to the Robb Report. Herjavec purchased the property almost three years ago for about $32 million.
A 26-foot-wide foyer, accessed via a private elevator, opens into a great room with floor-to-ceiling windows overlooking Central Park and the New York skyline. Finishes and furnishings include Venetian plaster ceilings, Brazilian herringbone wood floors and custom lacquered millwork in the kitchen.
Don't Miss:
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
<li>Want To Grow Your Wealth Passively? Unlock Real Wealth with <a href="https://www.benzinga.com/money/cityfunds-yield">Cityfunds&#8217; Exclusive 8% Yield Fund</a>.</li>
</ul>
The penthouse has four ensuite bedrooms, including the primary master that at 1,350 square feet is as big as many people's homes.
The homeowners association bill of $11,800 per month buys access to the building&#8217;s amenities, which include valet parking, a health club with a gym, private pool and spa, dining and screening rooms, a library and billiards room and a pet spa.
Herjavec, 61, put the lavish penthouse on the market after deciding to move to the West Coast with his wife Kym Johnson and their 6-year-old twins Hudson and Haven, according to People magazine.
"I love the place in NYC — it makes me smile every time we are there, but we are making a more permanent move to the West Coast so not sure we will get to use it much," Herjavec said in a statement to People.
Trending:
<ul>
<li>Elon Musk Is Bullish On Austin. Here&#8217;s <a href="https://www.benzinga.com/go/musk-austin">How To Invest In The City&#8217;s Growth Before He Floods It With New Tech Workers</a>.</li>
</ul>
Last year, Herjavec paid $26 million for an estate in Hidden Hills, a gated Los Angeles suburb where many Kardashian family members and other celebrities live. The price was the most ever paid for a home in Hidden Hills.
Herjavec's story is one of rags to riches. His family immigrated from Croatia to Canada when he was 8 years old. Until then, he didn't know he was poor. He learned the importance of customer relationships working as a newspaper deliveryman in the early 1990s.
He made his fortune in technology, founding BRAK Systems, which he later sold to AT&amp;T for CA$30.2 million ($22 million). Next, he started the information technology company The Herjavec Group, now called Cyderes, which has grown from three employees and $400,000 in sales to more than 300 employees and $223 million in revenue over the last 20 years.
What's the key to Herjavec's success?
"The best advice I would give to somebody is, don't ever start a business that you are not incredibly and deeply passionate about," Herjavec told Business News Daily. "It is hell, and you will spend more hours with your business than you will with your family and friends. You will have horrible days that will make you want to quit and question everything you have ever learned. Along that journey, if you don't absolutely love what you do, there is no way you will survive."
Read Next:
<ul>
<li>Dara Khosrowshahi-Backed Startup Lets You <a href="https://www.benzinga.com/go/dara-backed-startup">Become a Landlord with $100</a>.</li>
<li>Miami Is Expected To Take New York's Place As The US Financial Capital. <a href="https://www.benzinga.com/go/miami-financial-capital">Invest In It With $500 Before That Happens</a>.</li>
</ul>

Real Estate

Luxury With A Bite: 'Shark Tank' Start Robert Herjavec Selling NYC Penthouse For $38 Million

Goldman Sachs analyst Toshiya Hari maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Neutral and raises the price target from $107 to $118.

Goldman Sachs Maintains Neutral on Teradyne, Raises Price Target to $118

RBC Capital analyst Sean Dodge maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Outperform and lowers the price target from $25 to $18.

TDOC

RBC Capital Maintains Outperform on Teladoc Health, Lowers Price Target to $18

Goldman Sachs analyst Eric Sheridan maintains Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Neutral and raises the price target from $13.5 to $16.

SNAP

Goldman Sachs Maintains Neutral on Snap, Raises Price Target to $16

U.S. stocks traded higher midway through trading, with the S&amp;P 500 gaining around 1% on Friday.
The Dow traded up 0.41% to 38,243.14 while the NASDAQ rose 2.00% to 15,923.52. The S&amp;P 500 also rose, gaining, 1.02% to 5,099.85.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38458706/top-4-materials-stocks-that-may-explode-in-q2">Top 4 Materials Stocks That May Explode In Q2</a>
Leading and Lagging Sectors Communication services shares rose by 4.1% on Friday.
In trading on Friday, energy shares dipped by 2%.
Top Headline
Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) reported downbeat earnings for its first quarter on Friday.
Total revenues and other income stood at $83.083 billion, beating the consensus of $78.352 billion. Adjusted EPS stood at $2.06, missing the consensus of $2.20.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Biodexa Pharmaceuticals Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares shot up 85% to $1.33 after the company entered an exclusive license agreement with Rapamycin Holdings for the rights to eRapa.</li>
<li>Shares of Focus Universal Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCUV#NASDAQ">FCUV</a>) got a boost, surging 47% to $0.4150 after the company announced board approval for the spin-off of Lusher.</li>
<li>Universal Logistics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULH#NASDAQ">ULH</a>) shares were also up, gaining 31% to $43.15 after the company reported better-than-expected first-quarter financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>iClick Interactive Asia Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICLK#NASDAQ">ICLK</a>) shares dropped 42% to $1.50 after the company announced the termination of its merger agreement.</li>
<li>Shares of Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) were down 43% to $0.1636 after the company reported pricing of $2.7 million public offering.</li>
<li>Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) was down, falling 20% to $435.67 after the company reported worse-than-expected first-quarter financial results.</li>
</ul>
Also Check This Out: H<a href="https://www.benzinga.com/news/earnings/24/04/38459594/how-to-earn-500-a-month-from-dominos-pizza-stock-ahead-of-q1-earnings">ow To Earn $500 A Month From Domino&#8217;s Pizza Stock Ahead Of Q1 Earnings</a>
Commodities In commodity news, oil traded down 0.1% to $83.48 while gold traded up 0.1% at $2,345.20.
Silver traded down 0.5% to $27.21 on Friday, while copper rose 0.5% to $4.56.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.16%, London's FTSE 100 rose 0.76% while Spain's IBEX 35 Index rose 1.48% The German DAX rose 1.40% French CAC 40 rose 1.03% while Italy's FTSE MIB Index climbed 1.00%.
Bank lending to households in the Eurozone rose by 0.2% year-over-year to €6.875 trillion in March. Spain&#8217;s retail trade increased by 0.6% year-over-year in March versus a revised 1.8% gain in the earlier month, while unemployment rate increased to 12.29% in the first quarter.
The consumer confidence indicator in France declined to 90 in April versus a reading of 91 in the prior month.
Asia Pacific Markets
Asian markets closed mostly higher on Friday, with Japan's Nikkei 225 gaining 0.81%, Hong Kong's Hang Seng Index jumping 2.12%, China's Shanghai Composite climbing 1.17% and India's S&amp;P BSE Sensex falling 0.82%.
The Bank of Japan maintained its key short-term interest rate unchanged at its April meeting. Singapore&#8217;s manufacturing production declined 9.2% year-over-year in March versus a revised 4.4% increase in the prior month.
Economics
<ul>
<li>The Federal Reserve's preferred measure of inflation – the Personal Consumption Expenditure (PCE) price index – rose more than expected in March. The headline PCE price index rose from 2.5% in February 2024 to 2.7% year-on-year in March, beating forecasts of a 2.6% increase, the Bureau of Economic Analysis reported Friday.</li>
<li>U.S. personal income increased by 0.5% from the prior month in March, while personal spending rose by 0.8%.</li>
<li>The University of Michigan consumer sentiment was revised lower to 77.2 in April compared to a preliminary reading of 77.9, and versus 79.4 in March.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/top-stories/24/04/38459336/i-dont-want-you-to-lose-any-money-jim-cramer-on-this-industrial-stock-go-buy-ge-vernova">&#8216;I Don&#8217;t Want You To Lose Any Money&#8217;: Jim Cramer On This Industrial Stock: &#8216;Go Buy GE Vernova&#8217;</a>

Earnings

Eurozone

Intraday Update

Trading Ideas

BDRX

FCUV

ICLK

NUWE

SAIA

S&P 500 Gains 1%; Exxon Mobil Posts Downbeat Earnings

Goldman Sachs analyst Salveen Richter maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and lowers the price target from $28 to $19.

SAGE

Goldman Sachs Maintains Neutral on Sage Therapeutics, Lowers Price Target to $19

WIIM

AMAT

AVGO

ENTG

Shares of semiconductor stocks are trading higher following strong earnings from Microsoft, which could be lifting AI optimism.

Goldman Sachs analyst Toshiya Hari maintains Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) with a Buy and raises the price target from $130 to $156.

Goldman Sachs Maintains Buy on Impinj, Raises Price Target to $156

Goldman Sachs analyst Lizzie Dove maintains Hertz Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) with a Sell and lowers the price target from $7 to $4.

Goldman Sachs Maintains Sell on Hertz Global Holdings, Lowers Price Target to $4

<h4>Key Takeaways:</h4>
<ul>
<li>Sunho Biologics has no revenue or licensing income to draw on, making a loss of 133 million yuan last year as all its products remain at the R&amp;D or clinical stage</li>
<li>The company is rumored to be targeting just $50 million in proceeds, only a third of the $150 million it was thought to be seeking in its first IPO attempt last year</li>
</ul>
By Fai Pui
The market conditions may be dire, but Chinese drug developer&nbsp;Sunho Biologics Inc.&nbsp;needs the cash.
The loss-making biotech has secured the green light for an IPO, but the Hong Kong market is in a prolonged slump and has hardly been fertile ground for new listings. In the first quarter of the year, only 12 companies managed to debut in Hong Kong, raising just HK$4.7 billion ($600 million) between them. Those were the lowest quarterly IPO takings in 15 years, placing Hong Kong 10th&nbsp;in the global rankings behind emerging markets such as India and Saudi Arabia.
Rising U.S. interest rates have pushed up the cost of raising funds, leaving cash-hungry start-ups with limited financing options. Many pharmaceutical companies working on novel drugs have been draining their internal coffers to stay in business long enough to deliver clinical results.
However, Sunho Biologics did manage to secure just enough external financing last August to qualify for a further cash infusion through a stock market listing.
The company, which is developing therapies to treat cancer and immune disorders, enlisted help from the institutional investor Efung Capital, which specializes in biomedicine. The fund bought a 14.89% stake for 210 million yuan ($29 million), pushing the biotech&rsquo;s valuation to 1.41 billion yuan, equivalent to about HK$1.53 billion.
The financing lifeline enabled the company to cross the valuation threshold set by the Hong Kong Stock Exchange for unprofitable IPO applicants from the biotech industry. The rules require candidates to have achieved a market capitalization of at least HK$1.5 billion, with enough working capital to cover 125% of expenses for at least 12 months from the date of the listing documents. Nevertheless, Sunho Biologics faltered in its first listing attempt and had another go in February this year. Finally on April 15, its IPO application was&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2024/106227/documents/sehk24041500865.pdf">successful</a>.
Sunho, founded in 2018, needs deep pockets to continue working on cutting-edge treatments such as immunocytokines, proteins that bind to tumor cells and help activate the body&rsquo;s defenses against cancer. At the time of the first IPO filing last August, market watchers were expecting the company to seek as much as $150 million. The IPO scale will not be revealed until the listing process is formally initiated, but this time around the likely target is estimated at just $50 million, given the challenge of raising money in a depressed market.
Innovative drug stocks were once all the rage with investors. Despite huge R&amp;D costs, companies could hit the earnings jackpot if they managed to bring just one or two viable products to market. But the endeavor is not for the faint-hearted, as investors could easily lose their big bets. On the front page of the prospectus, Sunho does not mince its words about the risk, stating: &ldquo;There is no assurance that we will ultimately be able to develop and market our core products or any of our pipeline products successfully.&rdquo;
According to the company, six of its nine pipelines have already reached clinical trial stages. Three of them are core products, including two immunocytokines and an ADCC enhanced antibody, which also aims to boost the body&rsquo;s immune response. The prospectus describes Sunho&rsquo;s products as the world&rsquo;s fastest developing immunocytokines for the clinical treatment of cancer patients.
The substances are fusion proteins designed to recognize tumor-associated antigens and deliver a payload of cytokines, which control cells in the immune system and blood. Immunocytokines can bridge tumor cells and white blood cells, rather like bispecific antibodies. By activating various aspects of the immune system, they have the capacity to mount an enhanced, intensive attack on cancer lesions.
<h3>Raising Funds For Clinical Trials</h3>
At present, all Sunho&rsquo;s products are still under development or are in clinical trials. The company&rsquo;s 21 million yuan in revenue last year was mostly derived from interest on bank deposits, government subsidies and production contracts. But the income was dwarfed by bills for R&amp;D expenses alone, coming in at 53.17 million yuan and 43.04 million yuan in the last two years. The company has six products in either the first or second stages of clinical trials that would require a wad of cash to bring to fruition. Sunho was upfront in the prospectus about its funding needs, saying that all the IPO money would go towards completing trials for its three core products.
In the absence of product revenue, Sunho suffered losses of about 52 million yuan and 133 million yuan in the past two years. By the end of 2022 the biotech&rsquo;s cash and cash equivalents were down to just 1.82 million yuan, simply not enough to cover day-to-day expenses. The infusion of 210 million yuan from Efung Capital last year kept the company going. But the cash reserves had dwindled to 125 million yuan at the end of last year and dropped further to about 102 million yuan at the end of February, while the company faced 398 million yuan in short-term obligations, of which financial liabilities recorded at fair value stood at 317 million yuan.
The only other unprofitable biotech to list in Hong Kong this year is&nbsp;Qyuns Therapeutics&nbsp;(2509.HK), which is developing therapies for autoimmune or allergic conditions. It went public at a market value of nearly HK$4.4 billion, achieving a stunning debut when its price rose 23.7% on the first day of trade. However, among the seven unprofitable biotech stocks that listed in Hong Kong last year, only one has been able to reward investors with a price gain.&nbsp;Sichuan Kelun-Biotech&nbsp;(6990.HK) has seen its stock price more than double while all the rest have fallen below their listing price, now trading at discounts ranging from 37% to 69%. In this austere environment, it is hard to get investors excited about biotech stocks, whatever their potential.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Asia

Biotech

General

Sunho Biologics Gets Green Light For Downsized IPO

Goldman Sachs analyst Bruno Amorim maintains Cemex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CX#NYSE">CX</a>) with a Buy and raises the price target from $9 to $10.

Goldman Sachs Maintains Buy on Cemex, Raises Price Target to $10

RBC Capital analyst Mike Dahl maintains Tri Pointe Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPH#NYSE">TPH</a>) with a Outperform and raises the price target from $38 to $42.

RBC Capital Maintains Outperform on Tri Pointe Homes, Raises Price Target to $42

Ratings for Enovix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $22.6, with a high estimate of $30.00 and a low estimate of $12.00. Witnessing a positive shift, the current average has risen by 25.56% from the previous average price target of $18.00.
<img src="https://www.benzinga.com/files/images/story/2024/1714147271_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Enovix among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Derek Soderberg</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Tim Moore</td>
<td>EF Hutton</td>
<td>Maintains</td>
<td>Buy</td>
<td>$24.00</td>
<td>-</td>
</tr>
<tr>
<td>Derek Soderberg</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$17.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Enovix. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Enovix compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Enovix's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Enovix's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ENVX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Enovix analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Enovix</h2>
Enovix Corp is engaged in the business of advanced silicon-anode lithium-ion battery development and production. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable the widespread utilization of renewable energy.
<h3>Financial Milestones: Enovix's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Enovix's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 575.3%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Enovix's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -812.59%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Enovix's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -23.49%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Enovix's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -11.06%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Enovix's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.74, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENVX

Where Enovix Stands With Analysts

EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) underwent analysis by 25 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">13</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated EQT and provided 12-month price targets. The average target is $41.8, accompanied by a high estimate of $60.00 and a low estimate of $27.00. This current average has decreased by 0.81% from the previous average price target of $42.14. 
<img src="https://www.benzinga.com/files/images/story/2024/1714147261_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive EQT is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Mike Scialla</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$47.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$41.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>David Deckelbaum</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Hold</td>
<td>$43.00</td>
<td>-</td>
</tr>
<tr>
<td>Devin McDermott</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$37.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Cameron Bean</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$52.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Jean Ann Salisbury</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$34.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$35.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Lloyd Byrne</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$43.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$39.00</td>
<td>-</td>
</tr>
<tr>
<td>Umang Choudhary</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$43.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Lloyd Byrne</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$42.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$37.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Phillip Jungwirth</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Cameron Bean</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$40.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Doug Leggate</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Jean Ann Salisbury</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$27.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$39.00</td>
<td>$41.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to EQT. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of EQT compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of EQT's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into EQT's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EQT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on EQT analyst ratings.</a>
<h2>Delving into EQT's Background</h2>
EQT Corp is an independent natural gas production company with operations focused in the cores of the Marcellus and Utica shales in the Appalachian Basin, located in the Eastern United States. The firm focuses on executing combo-development projects for developing multiwell pads to meet supply needs, with a focus on maximizing operational efficiency, technology, and sustainability. Its main customers include marketers, utilities, and industrial operators in the Appalachian Basin. The company has one reportable segment and its revenue stems from three types of gas reserves: natural gas, natural gas liquids, and crude oil. All of the firm's operating revenue is generated in the U.S., with most revenue flowing from the Marcellus Shale field and through the sale of natural gas.
<h3>Financial Insights: EQT</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining EQT's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -28.89% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Energy sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: EQT's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 7.93%, the company may face hurdles in effective cost management.
Return on Equity (ROE): EQT's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.69%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): EQT's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.41%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.36.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Peeling Back The Layers: Exploring EQT Through Analyst Insights

Financial giants have made a conspicuous bullish move on Li Auto. Our analysis of options history for Li Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) revealed 27 unusual trades.
Delving into the details, we found 62% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we spotted, 22 were puts, with a value of $2,521,932, and 5 were calls, valued at $353,223.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $24.0 to $47.0 for Li Auto over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Li Auto options trades today is 3450.5 with a total volume of 18,959.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Li Auto's big money trades within a strike price range of $24.0 to $47.0 over the last 30 days.
<h3>Li Auto Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714147259_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$22.35</td>
<td>$22.25</td>
<td>$22.25</td>
<td>$47.00</td>
<td>$609.7K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">289</td>
</tr>
<tr>
<td>LI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$23.5</td>
<td>$22.2</td>
<td>$22.2</td>
<td>$47.00</td>
<td>$310.8K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">435</td>
</tr>
<tr>
<td>LI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$22.85</td>
<td>$22.3</td>
<td>$22.3</td>
<td>$47.00</td>
<td>$280.9K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">985</td>
</tr>
<tr>
<td>LI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$22.25</td>
<td>$22.15</td>
<td>$22.25</td>
<td>$47.00</td>
<td>$206.9K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">880</td>
</tr>
<tr>
<td>LI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$22.25</td>
<td>$22.15</td>
<td>$22.25</td>
<td>$47.00</td>
<td>$189.1K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">880</td>
</tr>
</tbody>
</table>

<h3>About Li Auto</h3>
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 376,000 NEVs in 2023, accounting for about 4% of China's passenger new energy vehicle market. Beyond Li One, the company expands its product line, including both BEVs and PHEVs, to target a broader consumer base.
Having examined the options trading patterns of Li Auto, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Li Auto's Current Market Status</h3>
<ul>
<li>With a volume of 6,961,132, the price of LI is up 6.56% at $25.01. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 12 days.</li>
</ul>
<h3>What The Experts Say On Li Auto</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $32.5.
<ul>
<li>An analyst from Barclays downgraded its action to Equal-Weight with a price target of $25. </li>
<li>Reflecting concerns, an analyst from Macquarie lowers its rating to Outperform with a new price target of $40.</li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Li Auto, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Smart Money Is Betting Big In Li Auto Options

6 analysts have expressed a variety of opinions on Associated Banc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASB#NYSE">ASB</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $23.17, along with a high estimate of $25.00 and a low estimate of $22.00. This upward trend is apparent, with the current average reflecting a 10.33% increase from the previous average price target of $21.00.
<img src="https://www.benzinga.com/files/images/story/2024/1714147253_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Associated Banc among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Terry McEvoy</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniel Tamayo</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Associated Banc. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Associated Banc compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Associated Banc's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Associated Banc's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ASB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Associated Banc analyst ratings.</a>
<h2>Delving into Associated Banc's Background</h2>
Associated Banc-Corp is a bank holding company. The company through its subsidiaries provides a broad array of banking and nonbanking products and services to individuals and businesses. The company operates in three reportable segments; Corporate and Commercial Specialty; Community, Consumer, and Business; and Risk Management and Shared Services. The majority of its revenue is derived from the Corporate and Commercial Specialty and Community, Consumer, and Business segments.
<h3>Associated Banc: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Associated Banc's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -65.18%. This indicates a decrease in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Associated Banc's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -75.61%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Associated Banc's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -2.33%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Associated Banc's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.22%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Associated Banc's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.62.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Associated Banc's Future

Financial giants have made a conspicuous bullish move on Taiwan Semiconductor. Our analysis of options history for Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) revealed 31 unusual trades.
Delving into the details, we found 41% of traders were bullish, while 38% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $268,516, and 23 were calls, valued at $3,753,617.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $80.0 and $140.0 for Taiwan Semiconductor, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Taiwan Semiconductor options trades today is 3446.93 with a total volume of 31,055.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Taiwan Semiconductor's big money trades within a strike price range of $80.0 to $140.0 over the last 30 days.
<h3>Taiwan Semiconductor Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714147253_0_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/19/24</td>
<td>$14.05</td>
<td>$13.85</td>
<td>$13.95</td>
<td>$130.00</td>
<td>$659.5K</td>
<td>9.1K</td>
<td>4.0K</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$14.2</td>
<td>$14.15</td>
<td>$14.15</td>
<td>$130.00</td>
<td>$557.5K</td>
<td>9.1K</td>
<td>866</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$14.1</td>
<td>$13.95</td>
<td>$14.01</td>
<td>$130.00</td>
<td>$326.1K</td>
<td>9.1K</td>
<td>2.0K</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/21/24</td>
<td>$6.45</td>
<td>$6.4</td>
<td>$6.44</td>
<td>$140.00</td>
<td>$304.2K</td>
<td>22.7K</td>
<td>3.5K</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$14.1</td>
<td>$13.95</td>
<td>$14.04</td>
<td>$130.00</td>
<td>$187.8K</td>
<td>9.1K</td>
<td>1.7K</td>
</tr>
</tbody>
</table>

<h3>About Taiwan Semiconductor</h3>
Taiwan Semiconductor Manufacturing Co. is the world's largest dedicated chip foundry, with almost 60% market share. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public as an ADR in the U.S. in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD, and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs. TSMC employs more than 73,000 people.
Having examined the options trading patterns of Taiwan Semiconductor, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Taiwan Semiconductor</h3>
<ul>
<li>Trading volume stands at 4,476,603, with TSM's price up by 0.96%, positioned at $137.89.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 83 days.</li>
</ul>
<h3>Professional Analyst Ratings for Taiwan Semiconductor</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $162.2.
<ul>
<li>Maintaining their stance, an analyst from Susquehanna continues to hold a Positive rating for Taiwan Semiconductor, targeting a price of $180. </li>
<li>Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Taiwan Semiconductor, targeting a price of $168. </li>
<li>An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $168. </li>
<li>Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Taiwan Semiconductor, targeting a price of $150. </li>
<li>Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Taiwan Semiconductor, targeting a price of $145. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Taiwan Semiconductor, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.